iBio (IBIO) Change in Interest Receivables (2023 - 2026)
iBio (IBIO) posted quarterly Change in Interest Receivables of $20000.0 for Q1 2026, up 42.86% year-over-year from $14000.0 in Q1 2025, and little changed quarter-over-quarter from $20000.0 in Q4 2025.
iBio (IBIO) Change in Interest Receivables (2023 - 2026) Analysis & Trends
iBio (IBIO) has reported Change in Interest Receivables for 4 consecutive years, with $20000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Interest Receivables rose 42.86% year-over-year to $20000.0; the TTM figure through Mar 2026 stood at $74000.0 (up 7.25% YoY), while the FY2025 annual figure was $62000.0, down 29.55% from the prior year.
- Change in Interest Receivables held at $20000.0 in Q1 2026 per IBIO's latest filing, from $20000.0 in the prior quarter.
- Across five years, Change in Interest Receivables topped out at $22000.0 in Q3 2023 and bottomed at $14000.0 in Q4 2024.
- Historically, Change in Interest Receivables has averaged $19000.0 across 4 years, with a median of $20000.0 in 2025.
- Annual changes were most pronounced in 2024 — Change in Interest Receivables tumbled 36.36% — and 2025, when it soared 42.86%.
- iBio's Change in Interest Receivables stood at $22000.0 in 2023, then sank by 36.36% to $14000.0 in 2024, then jumped by 42.86% to $20000.0 in 2025, then changed by 0.0% to $20000.0 in 2026.
- Business Quant data shows IBIO's Change in Interest Receivables at $20000.0 in Q1 2026, $20000.0 in Q4 2025, and $19000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | 20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20,000.00 |
| Dec 31, 2025 | 20,000.00 |
| Sep 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Dec 31, 2024 | 14,000.00 |
| Sep 30, 2024 | 19,000.00 |
| Jun 30, 2024 | 22,000.00 |
| Mar 31, 2024 | 22,000.00 |
| Dec 31, 2023 | 22,000.00 |
| Sep 30, 2023 | 22,000.00 |